Qun Lin

机构：Sun Yat-sen University, Wenzhou Medical University, Yale University, Sun Yat-sen Memorial Hospital, Wenzhou Central Hospital, Alexion Pharmaceuticals (United States), AstraZeneca (United States) · ORCID：0000-0002-9629-5733

发表论文 163 篇 · 总被引 8621 次 · h-index 43

代表论文

• Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis (2023 · JAMA Neurology · 被引 27)
• Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics (2023 · Cell Death Discovery · 被引 26)
• Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial (2024 · Journal of the Peripheral Nervous System · 被引 21)
• Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2− breast cancer: A phase 1b/2 trial (2024 · Med · 被引 14)
• Urolithin B Attenuates Cerebral Ischemia–reperfusion Injury by Modulating Nrf2-regulated Anti-oxidation in Rats (2023 · Neuroscience · 被引 13)
• Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study (2024 · Cell Reports Medicine · 被引 7)